A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms.

doi:10.1016/j.jmoldx.2013.07.009

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms.

The Journal of molecular diagnostics : JMD - 1 Jan 2014

Beau-Faller Michèle, Blons Hélène, Domerg Caroline, Gajda Dorota, Richard Nicolas, Escande Fabienne, Solassol Jérôme, Denis Marc G, Cayre Anne, Nanni-Metellus Isabelle, Olschwang Sylviane, Lizard Sarab, Piard Fabienne, Pretet Jean-Luc, de Fraipont Florence, Bièche Ivan, de Cremoux Patricia, Rouquette Isabelle, Bringuier Pierre-Paul, Mosser Jean, Legrain Michèle, Voegeli Anne-Claire, Saulnier Patrick, Morin Franck, Pignon Jean-Pierre, Zalcman Gérard, Cadranel Jacques

Abstract excerpt

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors have limited use as first-line treatment for mutated EGFR metastatic non-small cell lung cancer. The French National Cancer Institute has installed molecular genetics platforms implementing EGFR and KRAS testing. However, there is considerable uncertainty as to which detection methods should be applied for routine diagnosis. This study aimed to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to False Positive Reactions

Share to Gefitinib

Share to Molecular Diagnostic Techniques

Share to Nucleic Acid Amplification Techniques

Share to Quinazolines

Share to ras Proteins

Source

Open in PubMed

Identifiers

PMID: 24183959
DOI: 10.1016/j.jmoldx.2013.07.009

Genes

EGFR
KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms.PMID 24183959Read ↗

Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer.Semantic proximity Read ↗

Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project--part 1).Semantic proximity Read ↗

EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology.Semantic proximity Read ↗

A comparison of epidermal growth factor receptor mutation testing methods in different tissue types in non-small cell lung cancer.Semantic proximity Read ↗

The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced/metastatic NSCLC.Semantic proximity Read ↗

Clinical performance evaluation of the Idylla™ EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancer.Semantic proximity Read ↗

Molecular Diagnostics in Non-Small Cell Lung Carcinoma.Semantic proximity Read ↗

EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review.Semantic proximity Read ↗

EGFR Mutation Detection in Brazilian Patients With Non-Small-Cell Lung Cancer: Lessons From Real-World Data Scenario of Molecular Testing.Semantic proximity Read ↗

Clinical Performance Evaluation Of The Idylla™ Egfr Mutation Test On Formalin-Fixed Paraffin-Embedded Tissue Of Non-Small Cell Lung CancerSemantic proximity Read ↗

Validity of Targeted Next-Generation Sequencing in Routine Care for Identifying Clinically Relevant Molecular Profiles in Non-Small-Cell Lung Cancer: Results of a 2-Year Experience on 1343 Samples.Semantic proximity Read ↗

Development and Clinical Utility of a Blood-Based Test Service for the Rapid Identification of Actionable Mutations in Non-Small Cell Lung Carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.